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Abstract
It is a well-known fact that DHEA declines on ageing and that it is linked to ageing-related neurodegeneration,
which is characterised by gradual cognitive decline. Although DHEA is also associated with inflammation in the
periphery, the link between DHEA and neuroinflammation in this context is less clear. This review drew from
different bodies of literature to provide a more comprehensive picture of peripheral vs central endocrine shifts with
advanced age—specifically in terms of DHEA. From this, we have formulated the hypothesis that DHEA decline is
also linked to neuroinflammation and that increased localised availability of DHEA may have both therapeutic and
preventative benefit to limit neurodegeneration. We provide a comprehensive discussion of literature on the
potential for extragonadal DHEA synthesis by neuroglial cells and reflect on the feasibility of therapeutic
manipulation of localised, central DHEA synthesis.
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Background
From the recent literature, it is evident that the pro-
cesses of neuroinflammation and neurodegeneration are
inextricably linked. Given the sequestered nature of the
brain, which complicates research sample collection for
obvious reasons, many investigators seem to extrapolate
data generated from peripheral samples in attempts to
explain central events. However, as also illustrated in the
pages to follow, there is often a disconnection between
adaptation in the periphery versus those occurring cen-
trally. In our opinion, there are multiple reasons for this.
Firstly, the neuroimmune system is structurally distinct
from the peripheral system in that most immune func-
tions are mediated by cells specific to the nervous sys-
tem, such as microglia and astrocytes [1]. Incidentally,
although recent commentaries and research letters per-
taining to the identification of a lymphatic system in the
dural spaces are suggesting that the brain may be subject
to surveillance by immune cells circulating from the per-
iphery [2], not enough data exist with which to evaluate
the relative importance of these immune cells relative to
those residents in the brain. Secondly, the brain has a
preference for glucose as a substrate, as opposed to most
peripheral organs, such as the heart, which mainly derive
energy through fatty acid β-oxidation, which may affect
the outcome of adaptive—or maladaptive—metabolic re-
sponses differently in the brain to peripheral compart-
ments. Lastly, although the brain itself is subject to
glucocorticoid-mediated metabolic modulation, as in the
peripheral compartment, it is also directly affected
by—and thus adapts as result of—psychological input.
From this, it is clear that different factors come into
play centrally vs. peripherally in terms of adaptation to
stimuli. This questions the validity of treating neuroin-
flammation—especially in the context of chronic disease
aetiology—using the same strategies by which peripheral
chronic low-grade inflammation is addressed. It further
highlights the need for specific, central investigations for
the purpose of answering questions pertaining to central
physiological adaptation or maladaptation.
We have identified the hormone (also aptly referred to
as a neurosteroid) dehydroepiandrosterone (DHEA) as a
relatively under-researched hormone in the context of
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neurophysiology, despite its very clear association with a
plethora of clinical disease states. DHEA, which is pre-
dominantly synthesised in the human adrenal cortex,
also exists as a sulphated ester known as DHEAS, which
is formed when DHEA is processed by the enzyme ster-
oid sulphotransferase (SULT) [3, 4]. Of note, the major-
ity of DHEA in circulation exists as DHEAS due to it
having a stronger binding affinity for its carrier protein,
albumin [5]. DHEA is the precursor hormone to both
androgenic and estrogenic hormones and, as such, is
also synthesised to a smaller extent in human gonads. In
addition, and most relevant to the context of the current
topic, it is claimed to be synthesised de novo in the human
brain as well. In fact, DHEA concentrations in the human
brain have been shown to be higher than that in circula-
tion, while DHEAS concentrations are lower [4, 6], which
not only supports the theory of local synthesis, but also
testifies to the importance of this hormone centrally.
In the context of human health, DHEA has historically
been deemed to have limited importance, until low circu-
lating levels of DHEAS were associated with chronic and
age-related diseases such as diabetes, hypertension and
arthritis. [7–11]. In addition, it has since drawn much
media attention as being an “anti-ageing” supplement after
circulating levels were also reported to dramatically and
progressively decline with age [9, 12]. Most relevant to the
current context, abnormal changes in DHEA levels in
serum and cerebral spinal fluid (CSF) have also been re-
ported in the pathophysiology of neurodegenerative dis-
eases such as Alzheimer’s disease (AD), schizophrenia and
multiple sclerosis (MS), as well as neurocognitive patholo-
gies such as post-traumatic stress disorder (PTSD) (a sum-
mary of these reports is provided in Table 1). However,
much remains unknown about DHEA’s mode of action in
the human body or the reason for its age-related decline.
Therefore, and given the commonly accepted phenomenon
of accelerated ageing in many chronic disease states [13],
understanding the process of ageing and the physiological
role of DHEA in this process, may be of benefit to the
development of novel strategies in the treatment of these
enigmatic pathologies.
With this review, we provide a comprehensive sum-
mary of what is known about the role of DHEA in the
context of neurophysiology and ageing. This will be
followed by a discussion of specific topical issues, such
as the effect of sex and species, as well akowski the sites
for DHEA production. More specifically, relevant litera-
ture providing arguments for and against central, intra-
crine DHEA production is discussed in order to make
an interpretation on the likelihood of central DHEA bio-
synthesis taking place, as well as on the feasibility of
modulating central DHEA levels for therapeutic effect in
the context of ageing-related neuroinflammation and
ageing-related degeneration.
Process of ageing
Ageing is an inevitable, natural biological process charac-
terised by a progressive loss of physiological integrity
which results in impaired function and increased probabil-
ity of death. It is an extremely complex process which is
affected by a number of lifestyle and genetic factors that
may accelerate, ameliorate or even slow down the progres-
sion of ageing itself [13]. The process of ageing is com-
monly considered the main risk factor in the development
of neurodegenerative diseases such as Alzheimer’s disease
and Parkinson’s disease (PD) [14, 15]. Currently, the global
population is living longer as a result of the advances in
medicine and, consequently, such diseases are becoming
more prevalent.
Ageing itself is associated with cumulative oxidative stress,
chronic low-grade inflammation linked to age-related dys-
function of the immune system (termed immunosenes-
cence) and most notably, a decline in endocrine function
(termed endocrinosenescence) [13, 16]. The immediate sec-
tions to follow will focus primarily on immunosenescence
and endocrinosenescence—highlighting their intricately
linked aetiologies in the process of ageing itself, as well as in
age-related neurodegenerative pathologies.
Immune system maladaptation
Inflammation is an integral part of the innate immune sys-
tem: it not only acts as the first line of defence against
pathogenic attack and injury, but also serves to execute final
humoral immune effects (e.g. antibody-mediated pathogen
destruction). It is thus a normal physiological process that is
essential for the maintenance of homeostasis. An equally
Table 1 Summary of reports linking DHEA to neurodegenerative diseases and neurocognitive disorders
Disease Findings References
Alzheimer’s disease Significant decrease in serum DHEA and DHEAS levels when compared to aged-matched control patients [165–171]
Schizophrenia Data on both sides of the spectrum associate both abnormally elevated and declining levels of DHEA/DHEAS
with the disease. This opposing data could be related to the heterogeneity of the disease itself,
as well as other comorbid aetiological factors, which adds complexity to interpretation of this data.
[172–178]
Multiple Sclerosis Significantly higher CSF DHEA concentrations in relapsed patients relative to control patients with
stable neurological disease
[179]
Post-traumatic stress
disorder (PTSD)
Increased plasma DHEA and DHEAS levels when compared to unaffected control patients [180–186]
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normal consequence of the inflammation-facilitated repair
of tissues after any insult is the transient disruption of the
local cellular homeostasis of non-infected or uninjured cells.
This injury-repair cycle is efficient during youthful years, but
is affected by ageing, resulting in a relatively impaired ability
of the body to regenerate damaged tissues [13]. Systemically,
immunosenescent changes in the innate immune system are
characterised by a loss of phagocytic capacity, reduced effi-
ciency in leukocyte (neutrophil and macrophage) chemo-
taxis, reduced intracellular, but increased extracellular levels
of free radicals and an increase in production of “early” or
acutely responsive pro-inflammatory cytokines, such as
interleukin (IL)-1β, IL-6 and tumour necrosis factor
(TNF)-α [17–20], all of which contribute to a more
pro-inflammatory phenotype and which increase the burden
of tissue damage-recovery cycles. The loss in efficiency of
this process, coupled with an increased exposure to anti-
genic load and modern lifestyle associated chronic stressors,
results in the reduced ability of the body to maintain normal
immune function. This manifests as an increased risk for
malignancy, auto-immune responses, an impaired ability to
mount proper immune responses to stimuli and prolonged
inflammatory activity during acute infections [21–23].
Neuroinflammatory changes
As in the periphery, ageing of the brain is associated
with increasing inflammation and local oxidative
stress—also resulting in repeated tissue damage-recovery
cycles—which predisposes older individuals to develop-
ing neurodegenerative pathologies. Age-related neuroin-
flammation partly manifests as an increased reactivity of
microglia, the resident innate immune cells. In a healthy
brain, microglia are activated upon stimulation, but do
not necessarily release these pro-inflammatory media-
tors. In the aged brain however, microglia appear to not
only release pro-inflammatory mediators, but to do so in
an exaggerated and prolonged manner [24]. This appears
to be linked to the fact that microglia undergo signifi-
cant immunophenotypic and functional changes with
ageing: the activation status of microglia changes from a
quiescent to a “primed” state. This manifests as an in-
creased expression of the glial activation markers major
histocompatibility complex II (MHC II) and complement
receptor 3 (CD11b), which sensitises microglia to the exag-
gerated pro-inflammatory responses seen upon stimulation.
Animal studies have also suggested that chronic and
significant elevation of levels of pro-inflammatory cyto-
kines such as IL-1β may be linked to impaired memory
formation and long term potentiation (LTP) [24–27].
Systemically, IL-1β is released by monocytes upon rec-
ognition of a pathogen or site of injury, as well as by any
cell sustaining damage [28]. IL-1β enhances B and T cell
lymphocyte proliferation and stimulates IL-6 and TNF-α
production in many other immune cells. The systemic
elevation of circulating pro-inflammatory cytokines, par-
ticularly IL-1β, exerts a significant effect on the micro-
glial activation as well. However, in this context, the
age-related maladaptation seems to occur at different
magnitudes in the brain relative to the circulation. For
example, studies in mice have shown that stimulation of
the peripheral innate immune system with an intraperi-
toneal injection of either lipopolysaccharide (LPS) or live
E.coli bacteria resulted in a more prolonged and exagger-
ated elevation of IL-1β and IL-6 levels in aged brains
relative to those of younger mice [29, 30]. Interestingly,
the exaggerated and prolonged inflammatory response
was restricted to the brain and not paralleled with a
similar peripheral response. In addition, it was reported
that the hippocampus was more affected when com-
pared to other brain regions, such as the hypothalamus,
parietal cortex or prefrontal cortex [30]. The hippocam-
pus plays a critical role in memory formation, and con-
sequently, it is implicated in many neurodegenerative
pathologies, such as Alzheimer’s disease. These data give
credibility to the more recent suggestions that a severe in-
flammatory episode may trigger development of Alzhei-
mer’s disease [31, 32]. It also identifies the hippocampus
specifically as area of interest for preventative intervention.
However, before one can move on to interventions, it is
necessary to more fully understand the cause(s) of this ex-
aggerated neuroinflammatory outcome upon ageing. A
complexity is that the exact cause of the overactive re-
sponse in microglia from aged individuals has in fact not
been elucidated convincingly. We believe that the answer
might lie in the progressive and chronic elevation of gluco-
corticoid hormones that is also associated with ageing.
Endocrine dysfunction
The ageing hypothalamic–pituitary–adrenal axis (HPA)
Cortisol released into circulation can readily cross the
blood–brain barrier (BBB) and therefore can exert its ef-
fects both locally (in the brain) and systemically (in the
periphery), by binding to either of its two intracellular
receptors: mineralocorticoid receptor (MR) or gluco-
corticoid receptor (GR) [24]. A study in rats showed that
MRs have a significantly higher affinity for cortico-
sterone (the most abundant endogenous glucocorticoid
in rodents) than GRs; the latter is consequently only
bound by corticosterone upon complete saturation of
MRs during periods of highly elevated serum cortico-
sterone [33]. This phenomenon of preferential MR bind-
ing by the endogenous glucocorticoid cortisol (the most
abundant one in humans) is also well-documented in
humans [34]. Binding of cortisol to its receptors causes
it to translocate to the nucleus and decrease gene tran-
scription of pro-inflammatory cytokines—effectively the
body’s most important anti-inflammatory mechanism.
The brain expresses high levels of both MRs and GRs,
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with highest MR expression mainly in the hippocampus,
which has the highest of MR to GR ratio in the brain
overall [35].
To return to the context of this review, rat hippocam-
pal long-term potentiation (LTP), a correlation of synap-
tic plasticity and strength (and thus capacity for memory
formation), has been shown to be suppressed by GR ac-
tivation [36], which highlights this pathway as role player
in the pathology related to neurodegeneration, such as
Alzheimer’s disease. The hippocampus is a brain region
that is frequently highlighted in neurodegeneration re-
search. Of note, and as mentioned earlier, it is affected
more by peripheral inflammation than the rest of the
brain. Therefore, should the hippocampus be specifically
targeted in the treatment of inflammation-related neuro-
degeneration? In line with this question, how exactly do
glucocorticoids link ageing, inflammation and neurode-
generation? We put forward the following hypothesis: as
one ages, the repeated injury-repair cycles require
repeated glucocorticoid mediated anti-inflammatory
responses. Initially, the hippocampus is sensitive to
glucocorticoids due to a high expression of GR and MR
receptors. However, after numerous glucocorticoid
responses, the hippocampus downregulates receptor
expression—something which is indeed seen in acute
and chronic stress [37–40]. In fact, more than 30 years
ago, Sapolsky and colleagues reported aged rats to have
elevated basal corticosterone levels and an impaired cap-
acity for levels to return to basal after an acute stress re-
sponse [41]. This landmark paper proved to be the basis
of the glucocorticoid hypothesis, which postulated that
increasing age correlated with gradual loss of negative
feedback control resulting in the gross accumulation of
cortisol/corticosterone not only systemically, but also in
the brain [42]. The loss in negative feedback may be at-
tributed to a decrease in MR and GR expression in the
brain. For example, in cases and animal models of
neuropsychiatric diseases in which patients present with
hypercortisolemia, such as major depressive disorder
and PTSD, MR expression has been found to be down-
regulated specifically in the hippocampus [39, 43]. A
final possibility that we propose is that MR and GR acti-
vation may be insensitive to glucocorticoid binding in
aged human hippocampi. For example, it has been dem-
onstrated in human peripheral blood mononuclear cells
that in cells expressing high levels of GRs, GR affinity
for dexamethasone (a synthetic corticosteroid) is signifi-
cantly reduced when compared to individuals with per-
ipheral blood mononuclear cells (PBMCs) with lower
expression levels [44].
Given the age-related exaggerated and prolonged in-
flammatory responses discussed above, an exaggerated
anti-inflammatory counter in the form of increased gluco-
corticoid levels is probably to be expected. However, the
problem with the pro- and anti-inflammatory system
crosstalk lies in that this exaggerated response, which is
well-recorded in the ageing literature, is rendered insuffi-
cient to counter and resolve the inflammatory response by
the endocrine maladaptation discussed here.
The effect of age on the sympatho–adrenal–medullary
pathway (SAM pathway)
In parallel to its role in the HPA axis, the hypothalamus
also plays a critical role in the release of catecholamines,
such as epinephrine and norepinephrine from the adrenal
medulla, facilitated by sympathetic innervation of the me-
dulla [45]. Importantly, the context of this review is the
fact that catecholamines induce both the systemic and
localised upregulation of IL-6 synthesis, which can prompt
adrenocortical release of glucocorticoids [46–50]. In
addition, epinephrine and norepinephrine act synergistic-
ally with cortisol by upregulating glucose metabolism and
increasing cardiac output during acute periods of stress,
i.e. the “fight or flight” response.
Similar to the HPA axis, ageing also affects the SAM
pathway, mainly due to changes in the sympathetic ner-
vous system (SNS). Evidently, it appears that overall tonic
SNS activity increases with age [51]. Circulating norepin-
ephrine levels appear to increase whereas epinephrine
levels decline with age [51–55]. Whether these observa-
tions are due to impaired clearance or an increased output
by the adrenal medulla is still unknown. However, it is also
probable that the increasing circulating concentrations of
norepinephrine may in part be due to a spill over from
synaptic junctions at effector sites—which has already
been reported in at least one study [51]. Although no con-
sensus has been reached with regard to why these changes
may occur with age, it is very clear that they do occur.
When compared to the vast knowledge gathered on
the effects of age on cortisol and the HPA axis, relatively
little is known about the SAM pathway and even less so
about its effects on the inflammatory process. However,
hormones in the SAM pathway have demonstrated im-
mune modulating behaviour. For example, epinephrine
has been shown to potently inhibit LPS-stimulated human
monocytes from synthesising pro-inflammatory cytokines,
such as TNF-α and IL-12, as well as to stimulate the syn-
thesis of the anti-inflammatory cytokine, IL-10 [56]. On
the other hand, in the brain, norepinephrine may have a
pro-inflammatory effect in the hypothalamus. For ex-
ample, norepinephrine was shown to play a critical role in
foot shock stress-induced hippocampal and splenic pro-
duction of IL-1β [48]. Pre-treatment with the selective
beta-adrenergic receptor antagonist, propranolol, abro-
gated the IL-1β response. Furthermore, when animals
were treated with the microglial inhibitor, minocycline,
upregulation of IL-1β was completely inhibited in the
hypothalamus, but not the spleen [48]. These results are
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extremely relevant in the context of ageing, since it is
known that microglia play a critical role in age-related
neuroinflammation and the fact that noradrenaline levels
increase with age.
The effect of ageing on sex hormones
The HPA and SAM pathways are not the only endocrine
systems affected by ageing. It is commonly known that
the most evident effects of ageing occur through a
decline in sex hormone production. With regard to a
decline in androgen production and the synthesis path-
ways involved, the female menopause is probably best
characterised—in particular, the complete cessation of
oestrogen production by the ovaries [57]. Thus, after
menopause, DHEA becomes the major androgenic
hormone in the female circulation. Interestingly, a recent
review suggested that in aged individuals,
DHEA—although not able to facilitate ovarian oestrogen
production—may be able to serve as precursor for
tissue-specific oestrogen synthesis through intracrine
mechanisms [57]. According to this theory, oestrogen
would be synthesised in low concentrations at tissue
level (in any tissue where all the required steroidogenic
enzymes are present), where it would act in para- or
autocrine fashion, with little or no clearance into circula-
tion. Similarly, in males, extragonadal male androgen
production has also been demonstrated in peripheral tis-
sue [58]. With this in mind, a decline in adrenal DHEA
production with advancing age would therefore not only
have implications for reproduction, but also potentially
for other detrimental effects related to a decrease in
extragonadal oestrogen or testosterone production at
peripheral tissue level.
The decline of DHEA with ageing has been well-estab-
lished. Peak DHEA levels have been reported to occur
slightly earlier in life for females when compared to
males (15–19 vs. 20–24 years) [12], after which it stead-
ily declines, reaching levels of ≈20% of peak levels after
age 70 [59]. Epidemiological studies have correlated
DHEA levels to longevity in both humans and
non-human models [60, 61], while the decline of DHEA
has been linked to a number of ageing-associated
characteristics, including immunosenescence, cognitive
decline, osteopenia and sarcopenia [59].
From what has already been discussed, it is clear that
ageing is linked to several adaptations/maladaptations in
the endocrine system. What will become equally clear
from the literature to follow is the relative absence of
directly relevant data on DHEA, its involvement in these
processes and thus the effects its decline might have.
From studies conducted in contexts other than ageing, it
will become clear that DHEA has a significant role to
play. We discuss these potential roles below.
DHEA—the magic bullet?
Pre-clinical evidence suggesting neuroprotective effects
of DHEA
Since the turn of the century, several papers suggesting
beneficial effects after DHEA supplementation, in the
context of neuroprotection, have been published—we
have summarised findings illustrating the variety of
models used in Table 2. Reported benefits include
modulation of neurogenesis, neuronal function, metabol-
ism and longevity. However, a significant limitation to
available information is that the majority of these effects
have only been illustrated in in vitro and animal studies.
It is clear that DHEA is neuroprotective within these vari-
ous disease model contexts, but how is DHEA relevant to in-
flammation—and in particular to neuroinflammation-related
neurodegeneration?
Direct and indirect evidence for neuroprotective anti-
inflammatory effects of DHEA
To the best of the authors’ knowledge, very little evi-
dence for direct anti-inflammatory action of DHEA or
DHEAS in the brain or central nervous system (CNS)
has been elucidated per se. We were however able to
find at least three studies that have demonstrated the
anti-inflammatory effects of DHEA in vitro in models
relevant to the brain or CNS. The first demonstrated
that DHEA inhibits the synthesis of TNF-α and IL-6 by
cultured foetal rat astroglia in response to exposure to
Mycoplasma fermetans [62]. The second and third stud-
ies, which are also the most recent, were performed both
in vitro and in vivo [63, 64]. In the in vitro study, DHEA
treatment of cultured mouse microglia exposed to LPS
showed a significant reduction in TNF-α, IL-6, IL-12 and
monocyte chemoattractant protein 1 (MCP-1) mRNA ex-
pression when compared to LPS-exposed microglia re-
ceiving no treatment [64]. The in vivo study was an
experimental model of autoimmune encephalomyelitis
(EAE) in mice, which showed a significant reduction in
IL-1β and interferon gamma (IFN-γ) mRNA expression in
spinal cord tissue in animals treated with DHEAS when
compared to untreated EAE-affected animals [63].
Numerous other studies have illustrated the anti-in-
flammatory action of DHEA and DHEAS in systems and
disease models other than those related to the brain or
CNS (Table 3). Although this does not necessarily prove
that these same effects may be seen in the brain under
the same or similar circumstances, the possibility cannot
be discounted.
From these studies, it seems that DHEA exerts its
anti-inflammatory effects primarily by modulating either
the effects or production of pro-inflammatory cytokines.
However, it also appears that the same pro-inflammatory
cytokines have the ability to regulate DHEA production
in turn. For example, in macrophage-depleted primary
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murine leydig cell cultures, both IL-1 and TNF-α were
shown to inhibit androgen steroidogenesis by downregu-
lating the expression of cytochrome P450c17 mRNA—
which encodes for an enzyme that is critical to androgen
formation [65, 66]. TNF-α has shown similar inhibitory
effects in cultured porcine leydig cells by reducing the
binding of luteinising hormone (LH) or human chori-
onic gonadotropin (hCG) to the respective receptor—
which would stimulate steroidogenesis [67]. These au-
thors further suggested that the primary inhibitory ef-
fect of TNF-α was mainly by decreasing availability of
cholesterol, the initial substrate required for steroido-
genesis [67].
Regardless of how cytokines may inhibit the synthesis
of androgens, these studies provide a plausible explan-
ation for the age-related decline of DHEA not only sys-
temically, but centrally as well—given the relatively
pro-inflammatory status associated with ageing. Further-
more, since it has been shown that the inflammatory
maladaptation seen with ageing affects the brain to a lar-
ger extent (specifically the hippocampus), it is plausible
that the age-related decline of DHEA occurs even more
rapidly in the brain than it does the rest of the body.
In contrast to the idea that DHEA is largely beneficial,
a minority of studies have suggested that DHEA may
have neurotoxicity under specific conditions. In a model
Table 2 Evidence for beneficial effects of administered DHEA/DHEAS or metabolites reported in pre-clinical studies
Demonstrated beneficial effects Reference
General neuroprotective effects demonstrated both in vitro and in vivo in:
E18 Sprague–Dawley rat hippocampal cell culture model of N-methyl-D-aspartate (NMDA) neurotoxicity [187]
HT-22 mouse hippocampal cell line model of glutamate and amyloid-β neurotoxicity [188]
E18 Sprague–Dawley rat cerebral cortical cell culture anoxia model [189]
Mouse hippocampal neurodegeneration model [190]
Rats with induced forebrain ischemia model [191]
Rat hippocampal slice culture ischemia model [192]
Primary rat cerebellar granule cell anoxic and glucose deprivation model [193]
Mouse spinal cord ischemic injury model [194]
Rat inflammatory neurodegeneration model [195]
P19 neuronal NMDA-induced excitotoxicity cell line model [87]
Aged rat brain model [196]
Rat Corpus striatum (CS) and the nucleus accumbens (NAc) model of assessing effects of DHEA on monoamine oxidase (MOA) activity [197]
Human SH-SY5Y neuroblastoma cell line model assessing the effects of neurosteroids on mitochondrial bioenergetics [198]
Rat brain 3-nitropropionic acid (3-NP) induced neurotoxicity model [199]
Transient brain ischemic mouse model [200]
Primary male and female mouse cultured hippocampal neurons, as well as human SH-SY5Y neuroblastoma cell
line glucose deprivation model
[201]
Anti-apoptotic effects demonstrated in vitro in:
Undifferentiated P19 neuronal cell line model of NMDA-induced apoptosis [202]
PC12 rat pheochromocytoma cell line model of serum deprivation-induced apoptosis in adrenal medulla cells [203]
Primary rat embryonic cultured neural precursor cell model investigating the effect of DHEA and DHEAS on Akt phosphorylation [204]
Primary rat cerebellar granule cell model of hypoxia and glucose deprivation [205]
Anti-glucocorticoid effects demonstrated both in vitro and in vivo in:
Primary rat embryonic hippocampal neurons exposed to neurotoxic doses of corticosterone [206]
HT-22mouse hippocampal cell line model of glutamate and amyloid-β-induced neurotoxicity [188]
Mitigating effects on corticosterone-induced suppression of neurogenesis and survival of new neurons in dentate
gyri (hippocampi) of Lister Hooded Rats
[207]
Inhibitory effects of DHEA on glucocorticoid amplification in 3 T3-L1 adipocyte cell line and C57BL/6J mouse white
adipose and liver tissue
[208]
Inhibition of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) mediated conversion of cortisol by DHEA metabolites
in human skin samples
[209]
Suppression of 11β-HSD1 mRNA in HEK-293 rat cortical collecting duct cell line, as well as kidneys of C57BL/6J mice
and Sprague–Dawley rats
[210]
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of global cerebral ischaemic insult in rats [68], intraperito-
neal administration of a supraphysiological dose of DHEA
3 to 48 h after ischaemic injury was neuroprotective (e.g.
decreased neuronal death in the CA1 hippocampal region).
However, DHEA administration 1 h before or after the in-
sult exacerbated the effects of the injury. Given the known
anti-inflammatory role of DHEA, this may suggest that (at
least at this high dose) DHEA inhibited early inflammatory
or oxidative responses that were required for cytoprotec-
tion. Additionally, decreased cell viability was reported in
primary murine neuronal cultures and human neuroblast-
oma (SK-N-SH) cells after (24–72 h) exposure to a large
dose-range of DHEA—a result not seen in mixed neural or
glial cultures. Furthermore, the neurotoxic effects of DHEA
were abrogated by simultaneous treatment with DHEAS
[69]. From this, it is difficult to formulate an interpretation
on potentially toxic effects of DHEA. On the one hand, it is
certainly feasible that a high dose of an antioxidant such as
DHEA may have damaging effects, as this has been illus-
trated in the nutraceutical literature [70]. On the other
hand, the second study clearly highlights the limitations of
interpretations possible from single cell culture models,
although it does provide insight on the complexity of the
mechanisms at play. In our opinion, given the relatively lar-
ger body of evidence in support of a beneficial effect of
DHEA, significant concern is probably not warranted in
our context of intracrine DHEA production.
In order to further our understanding of how DHEA
may impact on the ageing brain, it is necessary to delve
deeper into the potential molecular actions and interac-
tions of DHEA and DHEAS.
Potential mechanisms for DHEA-mediated
neuroprotective effects
There are at least two ways via which DHEA can facili-
tate its effects centrally. Through following the conven-
tional steroidogenesis pathway, DHEA may be converted
to endpoint sex hormones, which would then activate
their respective receptors. Reviews by different groups
have suggested that DHEA can elicit genomic effects
through its conversion into testosterone and dihydrotes-
tosterone (DHT)—thereby activating androgen receptors
(AR)—as well as through its conversion into estradiol
and the subsequent activation of oestrogen receptors
(ER) [4, 6]. In support of this suggestion, it has indeed
been demonstrated that isolated neonatal rat cortical
and hypothalamic astrocytes can synthesise both testos-
terone and oestrogen from exogenous DHEA [71]. Alter-
natively, DHEA itself may be able to directly bind to and
activate these hormone receptors. Although no cell
membrane-bound or nuclear receptor has been de-
scribed to have an affinity specifically for DHEA or
DHEAS, a recent comprehensive review has revealed
that DHEA and DHEAS have affinity for a number of
membrane and nuclear receptors and binding sites [72],
allowing DHEA to directly activate receptors in the
brain and CNS specifically. DHEA is known to interact
with the cell membrane receptors γ-aminobutyric acid
type A (GABAA), N-methyl-D-aspartate (NMDA) and
sigma-1 (σ-1), as well as nuclear receptors such as per-
oxisome proliferator-activated receptor (PPAR)-α and fi-
nally neurotropin receptors such as tropomyosin
receptor kinase (Trk)-A, Trk-B and Trk-C [64, 72–74].
These potential mechanisms are briefly discussed in the
following paragraphs.
Firstly, GABAA receptors are ligand-gated chloride and
bicarbonate channels that induce hyperpolarisation to in-
hibit the postsynaptic potentials when activated [72].
DHEA and DHEAS (to a greater extent) have both been
shown to act as non-competitive antagonists of ionotropic
GABAA receptor-mediated activity in isolated neurosy-
naptosomes from Sprague–Dawley rat brains [75]. Simi-
larly, DHEAS was shown to block recombinant GABAA
receptor (GABAA R)-mediated currents in transfected
Table 3 Studies which have demonstrated anti-inflammatory effects of DHEA or DHEAS outside of the CNS
Disease/model Reference
Reduced regulation of IL-6 production in aged mice [211]
Reversed effects and decreased production of IL-4 and IL-6 in antigen induced immunosuppression in mice [212]
Reduced production of IL-6 in splenocytes of retrovirus infected mice as well as aged-induced immunocompromised mice [213]
Decreased production of IL-4 and increased production of IL-2 by concanavalin-A-stimulated PBMCs from patients with atopic dermatitis [214]
Reduction of TNF-α serum concentrations in obese Zucker rat model [215]
Inhibition of IL-6 production in isolated primary human peripheral blood mononuclear cells (PBMCs) [10]
Reduced production of IL-1, IL-6 and TNF-α in LPS-stimulated murine macrophage cell line [216]
Inhibition of TNF-α-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated gene transcription in
HuH7 human hepatocyte cell line
[217]
Suppression of pro-inflammatory genes (IL-1β, IL-6, TNF-α) in primary human HIV-positive macrophages, as well as feline
immunodeficiency virus (FIV)-positive felines
[218]
Inhibits acute LPS-induced microglia-mediated inflammation both in vivo and in vitro through the activation of TrkA-Akt1/2-CREB-Jmjd3
pathway and reduces IL-6, TNF-α, IL-12 and MCP-1 gene expression
[64]
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HEK293 cells [76, 77]. Another study of reversible spinal
cord injury in rabbits showed that DHEAS significantly
delayed the onset of ischemia-induced paraplegia [78].
However, despite widely reported, the exact mechanisms
of how DHEA or DHEAS may elicit neuroprotective ef-
fects through GABAA receptors still remain to be fully
elucidated. It is important to point out that DHEA ap-
pears to induce multiple effects through GABA recep-
tors—of note and in the context of ischemia injuries it
demonstrates antioxidant capacity, which is already ac-
cepted in literature and highlights the beneficial pleio-
tropic effects of DHEA.
Secondly, the NMDA receptor (NMDAR) is a cell
membrane bound receptor that is composed of a large
family of glutamate receptors. Glutamate receptors bind
to neurotransmitters and allosteric effectors which regu-
late transmembrane ion channels involved in learning
and memory, i.e. LTP [72]. DHEAS has been shown to
activate NMDARs in both rat hippocampal slices and
cultured mouse embryonic cultured neocortical neurons
[79, 80]. These reports suggest a more active function of
DHEA in the context of NMDARs.
Thirdly, sigma-1 (σ-1) receptors are associated with
cellular membranes, endoplasmic reticulum, nuclear
membranes and mitochondrial membranes of many cells
of neural origin, including astrocytes, oligodendrocytes
and microglia [72]. DHEA activation of sigma-1 recep-
tors improved memory deficits in induced in mouse
models [81]. In addition, the effect that DHEA and
DHEAS have on NMDARs appears to be linked to
sigma-1 receptor interactions. Evidence has shown that
DHEAS can potentiate NMDA evoked release of nor-
epinephrine in rat hippocampal brain slices through its
action as a sigma-1 agonist [82].
Fourthly, peroxisome proliferator-activated receptors or
PPARs are nuclear-associated transcription factors that are
capable of exerting pleiotropic physiological effects, such as
regulating lipid metabolism, participating in glucose homeo-
stasis and even having a role in apoptosis [83]. DHEA and
DHEAS may exert neuroprotective effects at nuclear recep-
tors such as PPARα. Specifically, inhibiting NF-kB binding
to PPARα. In a rodent study, the effects of DHEA and
DHEAS treatment in aged wild type (PPARα+/+) vs aged
PPARα knockout mice (PPARα−/−) were investigated. The
aged wild-type mice treated with DHEA and DHEAS exhib-
ited reduced tissue lipid peroxidation, reduced NF-kB activa-
tion in the spleen and lower pro-inflammatory cytokine
production when compared to knockout mice also treated
with DHEA and DHEAS [84]. It is worth noting though that
no specific binding affinity of PPAR for DHEA or DHEAS
has been reported [85]. Despite this fact, PPARα receptors
have increasingly been reported to have a role in mediating
oxidative stress and inflammation in brain pathologies such
as traumatic brain injury (TBI) [83, 86].
In line with these mechanisms, DHEA has been shown
to activate the pro-survival phosphatidylinositol-
4,5-bisphosphate 3-kinase/protein kinase B (PI3/Akt)
pathway. In fact, a study investigating the effects of
NMDA-induced excitotoxicity in culture mouse brain
cells, illustrated that DHEA was able to mitigate the det-
rimental effects by activating the PI3/Akt pathway
through a calcium dependent mechanism [87]. Similarly,
DHEA supplementation in aged Wistar rats was able to
increase the expression of phosphorylated-Akt in liver
tissue [88].
In terms of neurotropin receptors, DHEA has been
shown to bind with high affinity to the neurotrophin
growth factor (NGF) receptor TrkA in HEK293 cells
transfected with TrkA plasmid cDNA [73]. Binding of
DHEA to TrkA led to phosphorylation of the receptor
and activation of downstream pathways such as the Akt,
extracellular signal-regulated kinases (ERK)-1/2 and
SHC-transforming protein (Shc) signalling cascades [73].
In a similar study, also conducted in transgenic HEK293
cells, DHEA was shown to also bind to TrkB, which is
mainly activated by brain-derived neurotrophic factor
(BDNF), and TrkC, which is preferentially activated by
neurotrophin-3 (NT-3) [74]. However, this study showed
that DHEA binding only led to the phosphorylation and
activation of TrkC, but not TrkB [74]. It was noted that
DHEA bound these receptors by two orders magnitude
lower than that of the inherent neurotropins.
Finally, DHEA may also have a modulatory role in
cytoskeletal dynamics. In this context, DHEA has been
found to bind to the N-terminal of the dendritic local-
ised microtubule associated protein type 2C (MAP2C).
MAPs bind to and facilitate the dynamic microtubulin
polymerisation and DHEA was reported to increase the
length of dendrites expressing MAP2C [89]. This finding
is of particular relevance in the context of neurodegenera-
tive pathologies such as AD where a pathological change
in neuritic morphology is associated with disease [90].
Taken together, these studies indicate a significant
modulatory role of DHEA/DHEAS via its binding to a
wide variety of receptors. Of particular relevance to the
current topic, DHEA-linked anti-inflammatory—albeit
mainly demonstrated in circulation—and neuroprotec-
tive outcomes indirectly suggest that several benefits
may come from prevention of DHEA decline. Supple-
mentation is one clear avenue through which this may
be achieved.
Efficacy of therapeutic DHEA administration
DHEA supplementation has historically been used in the
treatment of reproductive-related diseases, particularly
in women, where it has been shown to alleviate
menopause-related pathologies such as vaginal atrophy
[91]. In support of our interpretation of benefit from
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maintaining DHEA availability, in diseases not related to
reproduction, DHEA supplementation has been shown
to be beneficial to both sexes in the treatment of numer-
ous other pathologies or conditions (see Table 4).
Despite these many clinical studies involving DHEA
supplementation, to the best of the authors’ knowledge,
the effects of exogenous DHEA supplementation has not
been directly assessed in clinical manifestations of neu-
rodegeneration or any related pathologies. Similarly,
there are also currently no clinical studies assessing the
effects of DHEA or DHEAS supplementation as an adju-
vant therapy for neurodegenerative diseases in either the
European or American clinical trial database.
In addition, it should be noted that other studies have re-
ported oral DHEA supplementation to show little to no
benefit in the treatment of other ageing-related pathologies
such as cognitive performance, lipid metabolism, glucose
metabolism, bone health and muscle function [92–94].
However, the available clinical studies collectively do
provide some insight. The conditions included in our
summary (Table 4), which all suggests benefit from
DHEA administration, are linked by the fact that inflam-
mation is a characteristic feature in all. Similarly, neuro-
inflammation is a critical hallmark of the generalised
pathophysiology of neurodegeneration and its occur-
rence appears to have a causative role in this degenera-
tive condition. Thus, given the already discussed
anti-inflammatory effect of DHEA (refer to Table 3), as
well as the anti-inflammatory therapeutic effect sug-
gested by the results just presented, theoretically, if one
can increase DHEA production at cellular level in the
central compartment, one should be able to alleviate or
prevent neuroinflammation and thus neurodegeneration.
Is it possible to stimulate extragonadal synthesis of DHEA
or DHEAS?
Since exogenous DHEA supplementation has yielded
varying benefit, an obvious alternative therapeutic—or
preventative—strategy to consider is whether it might be
naturally or artificially possible to increase endogenous
DHEA production.
From the sport and exercise literature, it is known that
exercise in older males can significantly increase serum
DHEA and DHEAS concentrations [95–101]. These re-
sults do not provide proof of extragonadal androgen
synthesis though, as moderate exercise is known to in-
crease gonadal testosterone production. However, inter-
estingly, similar effects of exercise have been reported
for DHEA in older, post-menopausal females [102–104].
In this population, where gonadal androgen production
is less possible, it is possible that extragonadal DHEA
production may occur in response to exercise.
Interestingly, a study conducted in Sprague-Dawley
rats has illustrated skeletal muscle to have endogenous
steroidogenic capacity and that acute bouts aerobic exer-
cise can significantly enhance the localised production of
DHEA in both male and female animals [105]. This adds
substantial support for our theory that extragonadal
DHEA synthesis may be elicited through intervention.
Furthermore, higher DHEAS levels have been reported in
long-term practitioners of alternative therapies such as tran-
scendental meditation and the ancient martial art of tai chi,
when compared to age-matched controls [106, 107]. Al-
though these studies do not prove that DHEA production is
stimulated by these practices, the relatively higher levels sug-
gest at least an effect to sustain long-term production rate.
In line with these results obtained in psychology-based prac-
tices, environmental enrichment in caged rats was linked to
increases in steroidogenic enzyme expression associated
with DHEA production, relative to unstimulated rats of the
same age [108]. Indeed, enrichment therapy is already being
employed to treat patients with dementia and Alzheimer’s
disease [109–113], although the authors could not find data
on the effect of this strategy on DHEA synthesis.
Considering this evidence, perhaps it is necessary to
first understand which tissues may possess the ability for
DHEA synthesis, before considering the feasibility of this
approach in the context of neurodegeneration.
DHEA biosynthesis
DHEA is produced during steroidogenesis, in a manner
dependent on mainly two classes of steroidogenic en-
zymes, namely the P450 enzymes and the hydroxysteroid
dehydrogenases [114]. Also, DHEA can be sulphated into
DHEAS via enzymes called steroid sulphotransferases
(SULT), while conversion of DHEAS back into DHEA is
mediated via steroid sulphatases (STS). DHEAS levels
continue to increase after puberty, peaking in the mid-20s,
Table 4 Illustrating the variety of studies reporting favourable
effects of DHEA/DHEAS supplementation in clinical pathologies
Disease state References
Autoimmune disease
Systemic lupus erythematosus [219–227]
Metabolic disease
Hypercholesterolemia [228]
Metabolic syndrome [229]
Genetic diseases
Hereditary angioedema [230]
Ageing-associated
Advanced age [231, 232]
Osteoporosis [233, 234]
Endocrine disorders
Hypopituitarism [235–238]
Adrenal insufficiency/Addison’s disease [239–246]
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after which levels begin to progressively decline with age
in both men and women [3, 12]. Serum DHEA and
DHEAS levels are thought to be almost exclusively main-
tained by their synthesis in the adrenal zona reticularis
[114]. However, in theory any tissue that expresses the
steroid enzymes can be classified as steroidogenic. In fact,
in the early 80s Fernand Labrie, a well-known endocrin-
ologist, was the first to note that prostate glands of pa-
tients with prostate cancer still had high levels of
dihydrotestosterone (DHT) even after castration [115]. He
illustrated that some peripheral tissues, such as the pros-
tate, possesses the steroidogenic enzymes needed to trans-
form DHEA and DHEAS into its androgenic and
estrogenic metabolites, thereby capable of exerting a rela-
tively more localised effect. The study of this unique ability
of peripheral tissues was termed “intracrinology” and has
subsequently gained some momentum [116]. Given the im-
portance of intracrine derived hormone production in
terms of female reproductive health, it is clear that investi-
gations into intracrinological mechanisms in other contexts
are warranted, such as in neurodegeneration and ageing.
Although it is known that intracrinology takes place in
peripheral tissues, all tissue types do not express the
same isoforms of the steroidogenic enzymes, nor are
they expressed in the same quantity or constitutively
expressed as we age. For example, a recent study in rats
demonstrated that the expression of several steroido-
genic enzymes decline significantly in the brain with age
[108]. It is important to have an understanding of where
the capacity for steroidogenesis exist, as well as to con-
sider sex and species differences, as these aspects signifi-
cantly impact on choices for experimental models, as
well as on the relevance and applicability of research
data gained in any particular model. It is not possible to
address steroidogenesis in its totality within the scope of
this review. Rather, in the next few sections we describe
some of these intricacies in the context of DHEA syn-
thesis specifically.
Production sites of DHEA
In terms of substrate delivery for steroidogenesis, the ste-
roidogenic acute regulatory protein (StAR) and cholesterol
side-chain cleavage enzyme (P450scc) are required for the
transport of cholesterol to the mitochondria and conver-
sion into pregnenolone, respectively. Interestingly, these
enzymes are expressed at significantly lower levels in the
Leydig cells of aged rat testes relative to those of younger
rats [117], which—since Leydig cells are the primary cells
for testosterone production in the male body—provides a
plausible explanation for the age-related decline of the
hormone in both rodents and humans. Interestingly, in
contrast, P450scc protein and mRNA expression in the
human adrenal glands appears to be relatively stable with
ageing [118, 119].
In the context of central intracrine production of
DHEA, P450scc mRNA has been detected in cultured
human astrocytes and oligodendrocytes (but not neu-
rons) in at least one study [120]. Many other studies
have detected steroidogenic enzyme expression in both
neurons and neuroglial cells in vertebrates other than
humans (refer to Fig. 1). We tabulated these studies for
brevity, but it is important to note that although ste-
roidogenic enzyme mRNA was detectable in these differ-
ent animal brain cell types, it is not clearly indicated to
what extent the level of gene expression may differ from
one cell type to another. Our interpretation of the data
presented in most of these cited studies, is that neuro-
glial cells appear to express higher levels of steroidogenic
enzyme mRNA relative to neurons, where levels were
barely detectable in some cases. This suggests that
mainly neuroglial cells are capable of significant intra-
crine synthesis, as already reported for peripheral tissue
other than gonads and adrenals [57, 58]. In contrast to
the P450scc findings, StAR mRNA expression in rat
brain brains has been shown to indeed decline signifi-
cantly with age [121], suggesting a relative decline in
substrate delivery similar to that reported for the testis.
Whether this occurs in human brain tissue could not con-
clusively be answered from the literature, but it certainly
cannot rule out. Nevertheless, the presence of both StAR
and P450scc in astrocytes and oligodendrocytes argues in
favour of sufficient substrate availability to indeed allow
for localised production of DHEA in these cells.
Another protein of potential relevance in the context
of cholesterol transport to the mitochondria has been
described. Translocator protein (TSPO), also known as
peripheral-type benzodiazepine receptor (PBR), a protein
mainly bound to the outer mitochondrial membrane,
has also been suggested to play a role in the facilitation
of cholesterol transport via StAR [138]. Whether the
presence of TSPO is critical in the transport of choles-
terol is a matter of controversy within literature. It was
shown in mice, with a specific TSPO gene knockout in
their Leydig cells, that testosterone could still be produced
despite the absence of what thought to be a critical protein
for the process [139]. Despite the uncertainty surrounding
its role in steroidogenesis, TSPO has recently been identi-
fied as a potential biomarker of neurodegeneration, as its
expression increases with inflammation and neurodegen-
eration associated with Alzheimer’s disease, HIV enceph-
alitis and MS [140, 141].
More specifically in terms of its function centrally, in vitro
experiments in primary human astrocytes have demon-
strated that various synthetic TSPO ligands of the
N,N-dialkyl-2-phenylindol-3-ylglyoxylamide class (PIGAs)
are capable of activating TSPO activity and stimulating neu-
rosteroidogenesis [142]. In fact, PIGAs have shown to be
neuroprotective in L-buthionine-(S,R)-sulfoximine (BOS)
Powrie and Smith Journal of Neuroinflammation  (2018) 15:289 Page 10 of 21
induced cytotoxicity of C6 rat glioma cells [143]. The mech-
anism of neuroprotection was associated with a reduction in
lipid peroxidation and inflammation, which was abrogated
in presence of the P450scc and StAR inhibitor aminoglu-
tethimide and was therefore thought to occur due to ste-
roidogenesis. Given the known anti-inflammatory and
antioxidant properties of DHEA, TSPO may be a role player
in the maintenance of DHEA levels.
Another fact in favour of local DHEA production in
the brain is the relatively increased demand for DHEA
in brain relative to the periphery. Firstly, steroid sulpho-
transferase isoform 2A1 (SULT2A1)—which increases
circulating DHEAS by sulphating DHEA, rendering it
bio-inactive [118]—seems to not be present in brain tis-
sue at all, while SULT2B1 expression has only been re-
ported for the prefrontal cortex, hippocampus and
cerebellum, but not for the cerebral subcortex or neo-
cortex [144, 145]. Secondly, sulphatase (STS) expres-
sion—which is responsible for conversion of DHEAS
into the bioactive DHEA—is generally very high in the
CNS [6]. Together, this suggests a relatively higher de-
mand for DHEA in the brain when compared to the per-
iphery. This scenario would also increase the likelihood
of mechanisms for local production to be in place.
The idea of de novo synthesis of DHEA and DHEAS in
the brain itself remains a highly debated topic in the field.
As mentioned, the human adrenal glands were initially
thought to be the only site of endogenous steroidogenesis,
apart from the gonads (i.e. testes, ovaries) which produce
DHEA and DHEAS to a lesser extent. However, the brain
has recently and controversially been highlighted as a pos-
sible alternative site for production. Given the neuroprotec-
tive and central anti-inflammatory effects of DHEA already
discussed, this possibility for intracrine DHEA production
has far-reaching implications for both neurodegenerative
disease and ageing—not only to increase our understanding
of the disease processes, but also in terms of development
of preventative and/or therapeutic strategies.
The first suggestion of DHEA synthesis in the brain
was already published in the 1980s—when DHEA and
DHEAS concentrations were reported to be higher in rat
brains than in circulation [146]. A few years later, similar
circumstantial evidence for DHEA synthesis in the hu-
man brain emerged [147]. DHEA was subsequently
commonly referred to as a “neurosteroid”, based on its
relatively increased central localisation. Although DHEA
can be detected in both animal and human brain tissue,
it remains unclear whether de novo synthesis indeed oc-
curs. For evident reasons, it is practically difficult to ac-
curately assess actual DHEA production in the human
brain, so that most data is generated from rodent
models. To add complexity to this topic, subsequent evi-
dence may suggest that a species difference in terms of
central DHEA levels may exist. In terms of criticism of
analytical techniques, it has for example been suggested
that DHEA levels in rat brain tissue reported in earlier
studies may have been overestimated due a lack of sensi-
tivity of the radio-immunoassays (RIA) technique used
at the time, which relied on antibody specificity to detect
the steroid hormones [148]. A newer method encompass-
ing solid phase extraction (SPE), high-performance liquid
chromatography (HPLC) and gas chromatography-mass
spectrometry (GC-MS) was developed to generate more
accurate data [148]. Ironically, nearly a decade later it was
reported by the same authors that this technique may in-
deed also be flawed when it came to the detection of
sulphated steroids [149]. They showed in rodent samples
that the levels of DHEA and PREG were higher in the
Fig. 1 Representative diagram of reported steroidogenic enzyme expression reported in different brain cell types. Species employed were rat,
unless otherwise additionally indicated (^mouse or *canine) [71, 122–137]
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lipoidal fraction of the SPE. It was suggested that choles-
terol contamination may have contributed to these find-
ings through cholesterol autoxidation, generating DHEA
and PREG, and that actual levels of DHEA and DHEAS
are likely extremely low or essentially non-existent in rat
brain tissue [149]. Interestingly, in the same paper, the au-
thors were able to confirm the presence of significant
amounts of both DHEA and PREG in human brain tissue
samples using this improved methodology. The exact
mechanisms of how cholesterol autoxidation leads to
DHEA and PREG generation remains to be elucidated.
Nevertheless, these results highlight the necessity of con-
sidering species in the design of experimental models. The
fact that DHEA cannot be detected in rodent brains may
be a function of generally lower levels when compared to
humans. Thus, although rodents can still be feasible
models, the parameters to be assessed, might have to dif-
fer depending on analytical sensitivity.
Given these methodological limitations in the meas-
urement of hormone levels directly, many indirect
methods have been employed to investigate the possibil-
ity of DHEA production centrally. However, results have
again posed more questions than answers. For example,
on one hand, P450c17 mRNA—which transcribes an en-
zyme that is crucial in the formation of DHEA—has
been detected in cultured human glial cells [120]. Subse-
quently, P450c17 mRNA expression has also been dem-
onstrated in the amygdala, caudate nucleus, cerebellum,
corpus callosum, hippocampus and thalamus of the hu-
man brain [119]. In addition and similarly to circulating
DHEA levels, the enzyme expression also declines with
age in the rat brain, which argue in favour of the possi-
bility for local DHEA synthesis [150]. Interestingly, the
age-related decline in P450c17 mRNA was reported to
be more pronounced in the cerebral cortex and cerebel-
lum, but not the hypothalamus [150]—this fact should
be further explored in order to determine its relevance.
However, the expression of P450c17 in the human
brain has been a topic of debate – at least two other
studies could not detect any P450c17 mRNA in the hu-
man cerebellum, hippocampus or temporal lobe and re-
ported no P450c17 activity in the temporal lobe [145,
151]. There are a variety of possible explanations for
these different results. Firstly, it is known that age has a
significant effect on steroidogenic enzyme expression, so
it is possible that this may have affected the results.
Indeed, in the study where the P450c17 mRNA was
detected, samples were pooled from patients between
the ages of 10 to 78 years. On the other hand, in at least
one of the studies failing to detect enzyme activity, sam-
ples were collected from a much older patient cohort
(80 years and older) [119, 151]. Secondly, in terms of the
failure of any group to report activity of the enzymes
which catalyse the reaction in the brain [6], there is
currently no way to determine at which rate potential
local DHEA synthesis would occur. An important con-
sideration here is that P450c17 expression reported for
the CNS is substantially lower than for the testes, which
exceeds it by nearly 200-fold [6]. It is therefore likely
that the conventional methods previously employed in
studies with negative outcome, may not have been suffi-
ciently sensitive to detect these possibly very low levels
of activity. Thus, the issue remains to be elucidated
across the ageing spectrum, to eliminate the potential
for a false negative outcome by using aged individuals.
Additionally, it is possible that localised DHEA biosyn-
thetic mechanism in the brain may differ from that at
other sites of local DHEA production. One group has in-
deed suggested that DHEA and DHEAS can be synthe-
sised in manner independent of P450c17. Their evidence
suggests that cultured human astrocytes and oligoden-
drocytes, but not neurons, could synthesise DHEA the
presence of a P450c17 and 3β-HSD inhibitor. It is sug-
gested that this alternative pathway may be dependent
on reactive oxygen species and produce DHEA from an
unknown “precursor” molecule other than pregnenolone
[120]. Although this study provided interesting data,
there is a limitation to the scientific rationale, as the au-
thors admitted that the P450c17 inhibitor used could
not block endogenous DHEA production in the glial
cells. At least one other lab has also speculated on the
possibility for an alternative pathway of DHEA produc-
tion linked to free radicals [152]. This is not impossible,
since a precedent in this regard exists: an alternative ster-
oid production mechanisms in the brain was clearly dem-
onstrated in the case of 21-hydroxylation, which appears
to be mediated through CYP2D instead of CYPC21 [153].
Apart from the debate on the capacity for intracrine
DHEA synthesis in the CNS, several theories have been
formulated in attempts to explain the relatively higher
DHEA and DHEAS concentrations in the central com-
partment. For example, it has been suggested that
DHEA in the brain may be produced from DHEAS de-
livered from circulation, through conversion by steroid
sulphatase (STS). Indeed, it has been shown that the hu-
man temporal lobe expresses high amounts of STS
mRNA as well as activity in the cerebral cortex relative
to subcortical white matter [145]. However, there are
two arguments against this hypothesis. Firstly, sulphated
hydroxysteroids such as DHEAS are hydrophilic and do
not readily cross the blood–brain barrier [154]. Although
sulphated steroids such as DHEAS and pregnenolone
sulphate may enter the brain through circulation via or-
ganic anion transporting peptides (OATP) transporting
them both ways, it would appear that OATP transport of
sulphated steroids favours movement out of the CNS,
not in [155]. However, a recent study investigating the
transport of DHEAS and PREGS through the blood
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brain barrier (BBB) of rats found that although PREGS
entered the blood brain barrier more readily, DHEA was
rapidly metabolised into androstenedione and androste-
nediol [156]. Further investigation found that the en-
zymes responsible for the rapid desulphatasion were
mainly localised the BBB capillaries as opposed the brain
parenchyma [156]. This argues that the DHEA in brain
is likely from peripheral sources as opposed to de novo
synthesis. However, it is important to note that the over-
all efflux of DHEAS through the BBB may still not be
rapid enough to account for the differences in concen-
tration in the brain versus the periphery.
Secondly, as already mentioned, DHEA and DHEAS
concentrations have been reported to be markedly
higher in the human brain than in circulation [147]. In
this study, DHEA concentrations were determined in
the brains of 10 subjects (9 females and 1 male, ages
ranging from 80 to 93). Nevertheless, in rat brains
DHEA concentrations were higher relative to circulation
and remained so even 15 days after an adrenalectomy
and/or orchiectomy [146]. This argues against the idea
of systemic delivery. However, as mentioned earlier the
techniques that were used to determine the concentra-
tion of DHEA in these studies may reassessed due to
possible cholesterol contamination.
Taken together there still exists a strong body of evi-
dence to support that de novo occurs in the brain. Al-
though it is near impossible to prove this specifically in
humans, as one will be faced with clear practical and
ethical hindrances, it is the opinion of the authors that
the human brain does indeed produce DHEA centrally.
In order to understand how DHEA may be produced in
the brain, the use of animal models may be the only way
to elucidate key pathways. This, however, does not come
without its challenges.
Practical challenges in steroidogenesis research
Several practical challenges have already been alluded to
in this review, such as methodological issues pertaining
to mRNA and protein determination, as well as gender-
specificity. A remaining consideration which will be
touched on in this section, is the importance of species
selection for investigations of this nature.
For example, it is important to consider that systemic ste-
roidogenesis in humans, higher primates and bovines differ
from rodents in two significant ways. Firstly, humans primar-
ily convert PREG to androstenedione through the Δ5 path-
way in the following manner: PREG » 17OH-PREG » DHEA
» androstenedione. Rodent steroidogenesis on the other
hand favours the Δ4 pathway; PREG » progesterone »
17OH-progesterone (17OH-PROG) » androstenedione
(Fig. 2). This is speculated to be the reason why humans have
high levels of circulating DHEAS, while in rodents levels are
significantly lower when compared to humans [157].
Secondly, in humans the adrenal gland is the main
source of DHEA production, but in rodents the gonads
are the main source, as the adrenal glands of most spe-
cies mice and rats appear to lack P450c17 enzyme activ-
ity [158, 159]. Although human gonads do produce
androgens such as DHEA, the reason for adrenal prefer-
ence of androgen production is not clear. The use of ro-
dent models in studying the systemic role DHEA has
thus garnered concern due the significant differences be-
tween humans and rodents. However, the fact that
DHEAS has been found in both human and rodent brain
tissue suggests that potential for de novo DHEA produc-
tion exists in the brain in both species. Therefore, ro-
dents could still serve as reliable model systems in
studying DHEA and its role in the brain.
Of specific interest in this context, it was recently dis-
covered that the precocial species of mouse, Acomys
Fig. 2 The process of steroidogenesis. Cytochrome P450 enzymes (blue font), hydroxysteroid dehydrogenases (orange font), reductases (purple
font), and steroid sulphatases (yellow font) and sulphotransferases (green font). Part of the pathway highlighted in green denotes the Δ5
pathway, which is favoured in human steroidogenesis, and the blue denotes the Δ4, which is favoured in rodent steroidogenesis
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cahirinus or Spiny mouse, possess adrenal glands that
express P450c17 and are in fact capable of producing
DHEA [160, 161]. This unique mouse has a longer ges-
tational period (± 39 days) when compared to other mice
and rats and unlike other rodents, has a brain growth
pattern that is comparable with humans at the time of
birth [162, 163]. It has also been shown in spiny mice
that cortisol is the main glucocorticoid in the blood, un-
like in rats where corticosterone is the main circulating
glucocorticoid [160, 161]. Most importantly, explanted
foetal, neonate and adult spiny mouse brain tissue in
culture have been shown capable of producing DHEA in
the presence of pregnenolone [164]. In addition, spiny
mouse also exhibit an age-related decline in DHEA syn-
thesis [163]. These mice may prove to be a particularly
reliable and relevant model for studying the mechanisms
of DHEA in many neurodegenerative disease states.
Conclusions
Based on the successes reported in experimental model
systems, DHEA has been proven to be beneficial to limit
progression of various inflammation-associated neurode-
generative diseases. From our review of the relevant litera-
ture, we conclude that central, intracrine synthesis of
DHEA is highly probable and we have highlighted several
mechanisms by which locally synthesised DHEA may
affect preventative and/or therapeutic benefit in the con-
text of neurodegeneration. Current literature is limited by
controversies regarding methodological accuracy and the
suitability of basic neuronal cell culture models. Taken to-
gether, this stresses the urgency for in vivo research specif-
ically focused at not only substantiating results from
experimental models, but also at elucidating in detail how
these processes may be harnessed for therapeutic benefits.
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